Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-11.69%
-0.25%
+5.60%
+2.96%
+3.28%
BIIB
Biogen
$135.20
Chart
$128.69 (+5.06%)
$129.44 (+4.45%)
$140.9 (-4.05%)
$203.3 (-33.50%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-11.69%
-0.25%
+5.60%
+2.96%
+3.28%
BIIB
Biogen
Current Price
$135.20
Login to view Biogen (BIIB) recommendation from the last 90 days from financial news and social media.
Chart
$128.69 (+5.06%)
$129.44 (+4.45%)
$140.9 (-4.05%)
$203.3 (-33.50%)
BIIB Latest Analysis
Global Renal Transplant Therapeutics Market is Expected to Cross ~USD 18 Billion by 2032 | DelveInsight. Global Renal Transplant Therapeutics Market is Expected to Cross ~USD 18 Billion by 2032 |. DelveInsightThe demand for renal transplant therapeutics is increasing due to several important factors. Chief among these is the global rise in kidney transplant procedures driven by the growing incidence of chronic kidney disease renal failure and end-stage renal disease (ESRD) all of which can c
Wed Aug 6, 2025
Earnings Snapshot: Biogen tops Q2 estimates raises FY EPS outlook.
Thu Jul 31, 2025
Biogen Q2 Results Top Estimates. Boosts FY25 Outlook . (RTTNews) - Biotechnology company Biogen Inc. (BIIB) reported Thursday that net income attributable to the company for the second quarter grew to $634.8 million or $4.33 per share from $583.6 million or $4.00 per share in the prior-year quarter.
Thu Jul 31, 2025
Biogen rises as Alzheimers therapy drives Q2 beat.
Thu Jul 31, 2025
Biogen raises annual profit estimates on strong demand for rare disease drugs.
Thu Jul 31, 2025
Biogens Earnings Outlook. Biogen (NASDAQ:) is gearing up to announce its quarterly earnings on Thursday 2025-07-31. Here'.s a quick overview of what investors should know before the release.Analysts are estimating that Biogen will report an Investors in Biogen are eagerly awaiting the company'.s announcement hoping for news of surpassing estimates and positive guidance for the next quarter.It'.s worth noting for new investors that stock prices can be heavily influenced by future proj
Wed Jul 30, 2025
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimers Association International Conference (AAIC) 2025. TOKYO and CAMBRIDGE Mass. July 30 2025 /PRNewswire/ -- Eisai Co. Ltd. (Headquarters: Tokyo CEO: Haruo Naito Eisai) and Biogen Inc. (Nasdaq: BIIB Corporate headquarters: Cambridge Massachusetts CEO: Christopher A. Viehbacher Biogen) announced today that the two-year...
Wed Jul 30, 2025
TNXP: 2Q25 Financial Update and Deep Dive Into TNX-1500. By Financial UpdateOn July 25 2025 Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) filed an 8-K in which it disclosed preliminary operating results for the second quarter of 2025. Net revenue from product sales for the quarter ended June 30 2025 was approximately $2.0 million compared to $2.2 million for the quarter ended June 30 2024. Net operating loss for the second quarter of 2025 was approximately $26.3 million compared to $78.8 mil
Tue Jul 29, 2025
Biogens ZURZUVAE Wins EMA Panel Backing For Postpartum Depression Treatment . (RTTNews) - Biogen Inc. (BIIB) Friday announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has backed marketing authorization for ZURZUVAE for the treatment of postpartum depression in adults following childbirth.
Fri Jul 25, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
BIIB Stock trends
BIIB Stock performance
BIIB Stock analysis
BIIB investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings